| Abuzaid Abbas Alawad Medani, MD | |
|
3400 Ministry Pkwy, Weston, WI 54476-5220 | |
| (715) 389-5127 | |
| Not Available |
| Full Name | Abuzaid Abbas Alawad Medani |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 3400 Ministry Pkwy, Weston, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528474079 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 64670 (Wisconsin) | Primary |
| 208M00000X | Hospitalist | 64670-20 (Wisconsin) | Secondary |
| Entity Name | Marshfield Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952347981 PECOS PAC ID: 2264345206 Enrollment ID: O20031106000590 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Entity Name | Beaver Dam Community Hospitals Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972188555 PECOS PAC ID: 2567370539 Enrollment ID: O20040210000666 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Entity Name | Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346239373 PECOS PAC ID: 2365433224 Enrollment ID: O20040519001426 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Entity Name | Flambeau Hospital, Inc. |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1700963048 PECOS PAC ID: 9032029871 Enrollment ID: O20070828000478 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Entity Name | Memorial Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1346239373 PECOS PAC ID: 2365433224 Enrollment ID: O20110526000807 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093221434 PECOS PAC ID: 5698071173 Enrollment ID: O20180208000096 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Entity Name | Lakeview Medical Center Inc Of Rice Lake |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093201832 PECOS PAC ID: 6103737820 Enrollment ID: O20180817001484 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1952890873 PECOS PAC ID: 5698071173 Enrollment ID: O20180904002962 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Entity Name | Flambeau Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194317966 PECOS PAC ID: 9032029871 Enrollment ID: O20210409000059 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abuzaid Abbas Alawad Medani, MD 1000 N Oak Ave, Marshfield, WI 54449-5703 Ph: (715) 387-5511 | Abuzaid Abbas Alawad Medani, MD 3400 Ministry Pkwy, Weston, WI 54476-5220 Ph: (715) 389-5127 |
News Archive
A researcher at the Cockrell School of Engineering at The University of Texas at Austin has received a four-year, $1.8 million grant from the National Institutes of Health (NIH) to develop a new technique for imaging blood flow across the surface of the brain that could help patients undergoing neurosurgery.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP GT, for the fully scalable production of gene therapy vectors, based on the Company's proprietary CAP technology.
Indiana University, the Regenstrief Institute and Indianapolis-based technology company LifeOmic have announced a first-of-its kind collaboration to advance the development of precision medicine, a personalized approach to disease treatment and prevention.
Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.
› Verified 5 days ago
Dr. Kshamata Shalini, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3400 Ministry Pkwy, Weston, WI 54476 Phone: 715-393-3000 | |
Matthew Hall, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3301 Cranberry Blvd, Weston, WI 54476 Phone: 715-393-3900 | |
J F Herbert R Macalalad, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3501 Cranberry Blvd, Weston, WI 54476 Phone: 715-393-1000 | |
Dr. Sanjay Kumar, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3501 Cranberry Blvd, Weston, WI 54476 Phone: 715-393-1000 | |
David A Polomis, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3301 Cranberry Blvd, Weston, WI 54476 Phone: 715-393-3900 | |
Dr. Udaya Shreesha, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3400 Ministry Pkwy, Weston, WI 54476 Phone: 715-393-3000 | |
Keshani Bhushan, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3400 Ministry Pkwy, Weston, WI 54476 Phone: 715-393-3000 |